Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 13/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107154 | 0.83 | OPRD1 (0.51) | OPRD1HPGDALDH1A1OPRK1MAPT | |
| SCHEMBL6936409 | 0.83 | OPRD1 (0.52) | OPRD1HPGDALDH1A1OPRK1MAPT | |
| SCHEMBL4576604 | 0.82 | ALDH1A1 (0.65) | OPRD1HPGDALDH1A1OPRK1MAPT | |
| SCHEMBL8527824 | 0.82 | HPGD (0.58) | OPRD1HPGDALDH1A1OPRK1MAPT | |
| SCHEMBL4830938 | 0.82 | HPGD (0.54) | OPRD1HPGDALDH1A1OPRK1MAPT | |
| SCHEMBL13620473 | 0.82 | OPRD1 (0.48) | OPRD1HPGDALDH1A1OPRK1MAPT | |
| SCHEMBL1989199 | 0.80 | OPRD1 (0.63) | OPRD1OPRM1 | |
| SCHEMBL14108185 | 0.79 | OPRD1 (0.48) | OPRD1HPGDALDH1A1OPRK1MAPT | |
| SCHEMBL10313332 | 0.78 | OPRD1 (0.74) | OPRD1OPRK1OPRM1 | |
| SCHEMBL10313333 | 0.78 | OPRD1 (0.74) | OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178763-A1 | Method of Treating Anxious Major Depressive Disorder | FREY JOSEPH (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110207745-A1 | SOLID FORMS OF 4--N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| US-7960389-B2 | 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178763-A1 | Method of Treating Anxious Major Depressive Disorder | DRD2, DRD4, HTR1D | OPRD1 22/4885HPGD 730/4885ALDH1A1 174/4885 |
| US-20110207745-A1 | SOLID FORMS OF 4--N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH | VHL, TPMT, NNMT | OPRD1 4300/4885HPGD 616/4885ALDH1A1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.